Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Office of Inspector General analysis could add momentum to reforms of the rebating system.

syringes_full_of_dollars
An Important Test Case For The Viability Of Biosimilars • Source: Shutterstock

More from Market Access

More from Pink Sheet